Treatment
What is Valeda Light Therapy?
What is Valeda Light Therapy?
Valeda Light Therapy
Experience the Benefits of Photobiomodulation with Valeda: A Groundbreaking Approach for Early Dry Age-Related Macular Degeneration (AMD)
A diagnosis of early dry AMD can be worrying, but there’s hope. The Valeda Light Delivery System by LumiThera is transforming how this condition is treated. Using advanced photobiomodulation (PBM) therapy, Valeda offers a non-invasive, innovative way to help protect and support your vision.
Understanding Photobiomodulation (PBM)
Photobiomodulation (PBM) is a safe, non-invasive light therapy that uses specific wavelengths of light – blue, red, and near-infrared – to stimulate cellular repair and reduce inflammation. By targeting the mitochondria, the energy centres of retinal cells, PBM encourages energy production and supports cellular regeneration.
In early dry AMD, retinal cells responsible for central and sharp vision gradually deteriorate. Valeda’s PBM therapy works to slow this degeneration, supporting healthier retinal function and potentially slowing the progression of the condition. Unlike conventional treatments that focus on managing symptoms, PBM aims to address the underlying cellular health of the eye.
How the Valeda Light Delivery System Works
The Valeda Light Delivery System uses a combination of wavelengths to gently penetrate the retina and stimulate retinal cells, helping them function more effectively. During this painless, non-invasive treatment, targeted light reaches the back of the eye, activating cellular repair processes. This boosts the production of adenosine triphosphate (ATP), the energy molecule for cells, while reducing oxidative stress, a key factor in AMD-related damage.
Treatment involves a series of short sessions, usually lasting just a few minutes each, over several weeks. Valeda helps improve retinal blood flow, reduce inflammation, and energize the cells essential for preserving clear central vision.
Valeda: The First Clinically Proven PBM Treatment for Dry AMD
Valeda is the first photobiomodulation (PBM) device clinically proven to treat early dry AMD. LumiThera’s research and clinical trials show that Valeda can meaningfully improve visual function in patients with early-stage AMD. Safe, non-invasive, and effective, Valeda offers an innovative option for those seeking proactive ways to preserve vision and enhance quality of life.
The Benefits of PBM Therapy for Early Dry AMD
- Non-Invasive and Painless: Valeda’s PBM therapy is a gentle, non-surgical treatment, providing an ideal alternative for patients seeking to avoid invasive procedures.
- Clinically Proven: Studies show that Valeda can enhance retinal function and slow the progression of early dry AMD, giving hope to those at risk of vision loss.
- Boosts Cellular Health: PBM targets the mitochondria in retinal cells, increasing energy production and reducing oxidative stress that can damage vision.
- Supports Long-Term Vision: By strengthening retinal cells, PBM therapy helps preserve and potentially improve visual function, helping you maintain independence and quality of life.
Take Charge of Your Eye Health with Valeda
For those with early dry AMD, Valeda provides a promising way to manage the condition before significant vision changes occur. Using photobiomodulation, Valeda targets the underlying causes of AMD, offering a proactive approach to preserving your eye health. This cutting-edge therapy supports retinal function, protects your vision, and brings reassurance for the future.
At Peter Ivins Eye Care, we are dedicated to advancing eye care technology. Valeda is one example of how we are shaping the future of vision care. Take the next step in managing early dry AMD and explore how Valeda can help safeguard your sight for years to come.
Schedule An Appointment Today!
We will do our best to accommodate your busy schedule.